Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac riskPeter Barrett‐Lee, Mark Verrill, J. Michael Dixon et al.|Annals of Oncology|2009Cited by 198
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognosesHelen Campbell, Mark Sculpher, David Epstein et al.|European Journal of Cancer|2011Cited by 46
How do patients want to learn of results of clinical trials? A survey of 1431 breast cancer patientsJudith M. Bliss, L. Johnson, Peter Barrett‐Lee et al.|British Journal of Cancer|2007Cited by 15
Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: Results from the UK NCRI Taxotere as Adjuvant Chemotherapy Trial (TACT)Penelope Hopwood, David Cameron, Peter Ellis et al.|Journal of Clinical Oncology|2005Cited by 7
Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-upPenelope Hopwood, David Cameron, Antonia Ridolfi et al.|Journal of Clinical Oncology|2008Cited by 3